HHS and peptide compounding in the U.S.: the October 2026 policy and its 10 conditions
On October 28, 2026, the U.S. Department of Health and Human Services (HHS) announced that it does not intend to act against pharmacies that compound drugs with six peptides —BPC-157, epitalon, KPV, MOTS-c, semax and TB-500— as long as they meet 10 conditions. It is not an approval and it is not a rule. This is what the document says, what it requires, what it says about "research use only" peptides, and what does not change.
What HHS announced
On October 28, 2026, the U.S. Department of Health and Human Services (HHS) announced an "enforcement discretion" policy: a decision not to take action against those who compound a drug with any of six peptides, as long as 10 conditions are met. The notice was published in the Federal Register on October 30 (91 Fed. Reg. 68526), signed by Secretary Robert F. Kennedy Jr.
- The six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500.
- Who it applies to: state-licensed pharmacies, federal facilities and licensed physicians compounding under section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act): preparations made for a specific patient, with a prescription.
- Who it does not: outsourcing facilities under section 503B, which are excluded.
- Who issued it: the HHS Office of the Secretary, not the FDA, the agency that administers section 503A.
The context: for a 503A pharmacy to use a bulk drug substance, it must have a U.S. pharmacopeia monograph, be a component of an FDA-approved drug, or appear on the so-called "503A bulks list." None of the six peptides meets those criteria today. In July 2026 the FDA's advisory committee on the matter (PCAC) voted in favor of listing them; the HHS policy covers the gap while that list is developed through rulemaking.
What the policy is not
- It is not a rule. It is a statement of how HHS intends to use its discretion. Per the notice itself, it establishes no rights for anyone and is not binding on HHS or the public.
- It approves no peptide. Anything compounded under the policy remains an unapproved drug: the FDA does not review its safety, effectiveness or quality before it reaches the patient.
- It adds nothing to the 503A bulks list. That only happens through FDA rulemaking: proposed rule, public comment and final rule.
- It is not permanent. It stays in effect until each peptide is addressed —included or excluded— in a final rule, and HHS may revisit it earlier, in whole or in part, if a safety signal or a product quality issue arises.
- It does not bind the states. State boards of pharmacy keep their authority and may restrict or prohibit these preparations.
"Draft" or "interim"?
Both words are correct, and both are in the Federal Register notice. HHS announces the availability of a draft and opens public comment until November 13, 2026 (Docket No. HHS-OASH-2026-0496). At the same time it calls the policy interim, because it applies only while the 503A bulks list is being developed. That is why Arnold & Porter titles its analysis with "draft" and Holland & Knight with "interim": they describe two features of the same document.
HHS's 10 conditions for pharmacies compounding peptides
The discretion applies only if all ten conditions are met at once. We summarize them from the Arnold & Porter and Holland & Knight analyses:
- Only these six substances. The peptide must be on the policy's Appendix A list: BPC-157, epitalon, KPV, MOTS-c, semax or TB-500.
- Identity and route per Appendix B. The substance must match the identity described there —amino acid sequence, chemical structure, molecular weight and formula— and stay within the route of administration that appendix sets for each peptide.
- Registered source and a valid COA. The substance must come from a facility registered with the FDA (section 510) and arrive with a valid certificate of analysis (COA), with results for identity, purity, potency and the absence of contaminants such as endotoxins, heavy metals, microbial contamination and impurities.
- Original manufacturer identified. The original manufacturer —not a repacker or a distributor— must be registered with the FDA and comply with current good manufacturing practice (cGMP), and the physical location of its facility must appear on the COA. If the substance passes through a repacker, relabeler or reseller, that entity must have validated and documented the manufacturer and its COA.
- Reporting. The compounder must report serious adverse events and product quality issues to the FDA's MedWatch program and to the states where the product is compounded and sent.
- Labeling. The product must state: "This is a compounded drug product. Not for resale."
- A single active ingredient. No blends: one listed peptide per product. According to HHS, that makes it easier to attribute an adverse event to a specific substance.
- Oral forms need backing. If the peptide is compounded in an oral dosage form, the compounder must keep documentation that the formulation achieves adequate oral bioavailability in humans.
- Cleared syringes only. The only delivery device that may accompany the product is an FDA 510(k)-cleared syringe.
- The rest of the law still applies. Compounding must meet all other applicable FD&C Act requirements: among them, not compounding under insanitary conditions and having a valid prescription for a specific patient.
Several of these conditions are not new: the registered source, the valid COA and the individual prescription are already required by section 503A. What is new is the full set, and that it applies to peptides that are not on the list.
The COA as the starting point
Of the whole text, what matters most to anyone working with peptides is in conditions 3 and 4. The regulator does not treat the certificate of analysis as a marketing extra: it makes it an entry requirement. Without a valid COA —identity, purity, potency and contaminants— and without knowing which facility manufactured the substance, the policy simply does not apply. And a reseller cannot just pass the document along: it must have validated the manufacturer and its certificate.
That is the standard worth taking away, whatever the compound: an analysis that can be independently verified, or nothing.
Where Renova stands
It is worth saying plainly: this policy neither covers nor authorizes our products. What Renova offers are reference materials for laboratory research (RUO): research use only, not for human or veterinary consumption. They are not pharmacy-prepared drugs and are not dispensed by prescription.
The documents are not the same thing either. The certificates we publish at /en/coa/ are analyses by an independent laboratory —Janoshik Analytical, by HPLC and mass spectrometry— of the identity and purity of the material tested, and each one can be checked directly with the lab. They are not the manufacturer's COA the policy describes, nor do they cover every test it lists. What we share is the principle: publish the analysis and let anyone verify it. How we work is described in Our process.
What HHS says about "research use only" peptides
There is no ambiguity here. HHS states that one goal of the policy is to discourage the widespread use of peptides labeled "research use only" supplied by foreign manufacturers, which in its view pose a risk to U.S. patients, by offering a more controlled alternative instead: pharmacy compounding, by prescription. Holland & Knight adds that the policy does not extend to "research use only" grade ingredients, and advises pharmacies to stop sourcing them.
Put another way: the policy does not endorse the research-peptide market; in part, it aims to move that demand toward the pharmacy. Anyone reading it as backing for any research-peptide vendor, ourselves included, is reading it backwards.
The objections
- The FDA's scientific reviewers recommended the opposite. The FDA's Center for Drug Evaluation and Research (CDER) recommended against adding any of the six peptides to the 503A bulks list, and the policy's Appendix B acknowledges it. The advisory committee voted in favor, and HHS relied on that vote.
- A citizen petition opposes it. The Partnership for Safe Medicines filed a petition with the FDA on October 23, 2026 (Docket No. FDA-2026-P-13366) asking that these peptides not be allowed to be compounded through enforcement discretion.
- Oversight is limited. Arnold & Porter notes that FDA registration is not an inspection, that the FDA inspects relatively few 503A pharmacies, and that adverse event reporting is a condition of the policy, not a statutory duty, with no clarity on how compliance will be overseen.
- It is a change of practice. Hall Render and Arnold & Porter highlight how unusual it is for the policy to come from HHS rather than the FDA. Arnold & Porter adds that the FDA has used this tool mostly in emergencies and shortages, not to widen access to unapproved drugs.
What changes in the Dominican Republic
Directly, nothing. It is a U.S. federal policy on how a U.S. law is enforced against pharmacies and physicians in that country. It does not alter the Dominican framework, which we explain in Are peptides legal in the Dominican Republic?
What it does leave is a useful reference. When a regulator defines the conditions under which it tolerates these six compounds, the list starts with verifiable documentation: identity, purity, contaminants and origin. It is a reasonable yardstick for evaluating anyone selling these compounds, in any country.
What comes next
- November 13, 2026: the public comment period on the draft closes.
- After that: HHS may keep, modify or withdraw the policy. Because it is enforcement discretion, it can do so without a new comment process.
- The decision that matters: FDA rulemaking on the 503A bulks list. As of November 2, according to Arnold & Porter, there was still no proposed rule for these peptides, and the full process may take years.
Sources
- Arnold & Porter — HHS Announces Draft Enforcement Discretion Policy Paving Way for Pharmacies to Compound Certain Peptides While FDA Rulemaking Is Pending (Nov 2, 2026)
- Hall Render — HHS, Not FDA, Takes the Lead on Peptide Compounding (Nov 4, 2026)
- Holland & Knight — HHS Issues Interim Enforcement Discretion Policy for Compounding of 6 Peptides (Nov 4, 2026)
- Federal Register — HHS notice of availability, 91 Fed. Reg. 68526 (Oct 30, 2026)
⚠ Research use only. Not for human or veterinary consumption. This article is informational and is not legal or medical advice.